Thinly traded micro cap Enochian Biosciences (NASDAQ:ENOB) rockets 292% premarket on robust volume in reaction to its announcement that
it has completed a meeting with the FDA during which there was “strong
alignment” between its planned development strategy for ENOB-HV-01 and
comments from agency reviewers.
It plans to file an IND next year.
The company says ENOB-HV-01 is a novel approach to
autologous stem cell transplantation that may be able to cure HIV via
increasing engraftment of gene-modified cells that are resistant to HIV
infection.
https://seekingalpha.com/news/3581065-enochian-biosciences-up-big-on-advancement-of-potential-hiv-cure
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.